"Safety and disease-related outcomes of #mCRPC patients treated with radium-223 then 177Lu-PSMA in the #RALU study. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss these results on UroToday > https://t.co/XJS9XTt2jh @Bayer" (@urotoday)

Cutting-edge predictive modeling for 177Lu-PSMA-617 therapy in mCRPC! 🧠 Join @ProfKHerrmann @UniklinikEssen and @PhillipKooMD @BannerHealth as they explore the potential of predictive models to optimize treatment outcomes > https://t.co/9GydPTjqum (@urotoday)

@DrRanaMcKay @UCSanDiego and @CaPsurvivorship @DanaFarber discuss the #RadiCaL trial, a phase II study exploring the use of radium in #mRCC with bone metastases and the benefit of Radium-223 with Cabozantinib vs cabozantinib alone. #WatchNow > https://t.co/QlEGZlDf4r @theNCI (@urotoday)

177Lu-PSMA-617 therapy in chemotherapy naïve #mCRPC patients: a single center experience. Presented by Raksha Kulkarni, MD @IcahnMountSinai. #SNMMI23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/QHuwlo8Eq0 @SNM_MI (@urotoday)

Dual PSMA/FDG PET/CT for assessing eligibility and predicting response in #mCRPC pts undergoing 177Lu-PSMA-617 radioligand therapy: a post-#VISION analysis. Presentation by Anushna Babu @aiims_newdelhi. #SNMMI23 coverage by @zklaassen_md > https://t.co/DmoIIwO1Xv @SNM_MI (@urotoday)

WATCH: Insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in #mCRPC. @CaPsurvivorship @DanaFarber https://t.co/fgrk40PLKG (@TargetedOnc)

In this video, Alicia Morgans, MD, MPH, discusses lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. #mCRPC #pcsm | @DanaFarber @CaPsurvivorship https://t.co/YxhijlXaiX (@TargetedOnc)

Why is the VISION trial on this list? At the time of the VISION trial there was no approval for Pluvicto in prostate cancer. Not giving it is appropriate. The control arm is a different story. (@ClarkHenegan)

WATCH: A discussion on the VISION and TheraP trials of lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. #mCRPC #pcsm | @CaPsurvivorship @DanaFarber https://t.co/FFSfQmt3KR (@TargetedOnc)

This is appropriate use! @SNM_MI consensus statement on patient selection and appropriate use of ¹⁷⁷Lu-PSMA-617 radionuclide therapy. https://t.co/T7vw6fWMmG #NuclearMedicine #RPTherapy #ProstateCancer @thomashopemd @morr316 (@JournalofNucMed)

.@urotoday featured @DrScottTagawa and colleagues’ ongoing, phase 3 #ClinicalTrial comparing 177Lu-PSMA-617 + standard of care vs. standard of care alone in pts. w/ metastatic hormone-sensitive #ProstateCancer presented at #ASCO23. https://t.co/yFxv5fm8o8 (@WCMGUcancer)

@DrRanaMcKay @UCSanDiego and @CaPsurvivorship @DanaFarber discuss the #RadiCaL trial, a phase II study exploring the use of radium in #mRCC with bone metastases and the benefit of Radium-223 with Cabozantinib vs cabozantinib alone. #WatchNow > https://t.co/QlEGZlDf4r @theNCI (@urotoday)

"Safety and disease-related outcomes of #mCRPC patients treated with radium-223 then 177Lu-PSMA in the #RALU study. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss these results on UroToday > https://t.co/XJS9XTt2jh @Bayer" (@urotoday)

Not sure until we see PSMA PET: agree with @drlouiseemmett - SUVmean is key... Outcome will be driven by control of prostate cancer rather than toxicity with either Lu-177 or Ra-223. We've treated several nonagenarians with PSMA-617 with favourable outcome. (@DrMHofman)

Real-world safety and effectiveness of radium-223 in patients with #mCRPC treated in the US: the non-interventional #REASSURE study. Presented by Daniel Song, MD @HopkinsMedicine. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/GzZbQytult @ASCO (@urotoday)

#PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 + standard of care and standard of care alone in patients with #mHSPC. Presentation by @DrScottTagawa @WeillCornell. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/KmhPyIk4Mi @ASCO (@urotoday)

“A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant #prostate cancer with bone metastases (COMRADE): A trial in progress.” at #ASCO23 @ASCO (@RutgersCancer)

PSMAddition: Ph 3 trial of 177Lu-PSMA-617 + SoC and SoC alone in mHSPC @DrScottTagawa @urotoday #ASCO23 🔹Target 1,126 pts 🔹177Lu-PSMA-617 (7.4 GBq q6 wks, max 6 cycles) + SoC or SoC alone (ARPI + ADT) 🔹Primary EP: rPFS by BICR 🔹Key Secondary EPs: OS, PSA90, TT mCRPC 🔹1st… https://t.co/G3hJ7c8mPq (@zklaassen_md)

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer. ☢️No G4 AEs or DLT 🧬PSA50 response % 66 ☢️ ORR is 78% ☢️Promising but need to see comparative study! @ASCO @OncoAlert #ASCO23 @sophia_kamran @FatimaKarzai… https://t.co/7aMd2o7MB7 (@DrYukselUrun)

Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant #ProstateCancer #mCRPC treated in the US: the non-interventional #REASSURE study - Daniel Song, MD @HopkinsMedicine. #ASCO23 coverage by @tchandra_uromd > https://t.co/gqjdXTck1v (@urotoday)

Tumor dosimetry of 177Lu-PSMA-617 for the treatment of #mCRPC: Results from the #VISION trial sub-study. Presentation by Bernd Krause @unirostock. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/lkRjKaUQMp @ASCO (@urotoday)

Thank you, @urotoday, for the excellent coverage of the #COMRADE trial at #ASCO23! I'm honored to have presented the study under mentoship of @DrRanaMcKay on the combination of olaparib and radium-223 for men with #mCRPC and bone metastases. #ProstateCancer @MAHIMRes @harvardmed (@Jani_Chinmay)

@NANETS1 Toronto: Great talk by @JaydiDelRivero on pheo/para “the great mimics” - remember all need genetic testing! Also, consider the Lutathera trial now open for PPGL! @LACNETS @PheoPara @netcancerday @CarcinoidNETs @HealingNET1 @CureNETs (@lisayentwin)

"Safety and disease-related outcomes of #mCRPC patients treated with radium-223 then 177Lu-PSMA in the #RALU study. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss these results on UroToday > https://t.co/XJS9XTt2jh @Bayer" (@urotoday)

we need to rediscover the positioning of 223-Ra in CRPC. Benefit to patients. Improve QoL and OS. @jamayasaumet @BayerEspana #XOFIGO @SEMNIMoficial (@DrJaVallejo)

🎉 Happy #ClinicalTrialsDay! We are thrilled to announce the completion of randomisation for #UpFrontPSMA, a major milestone in advancing research for hormone-sensitive metastatic prostate cancer with Lu-177 PSMA-617. Results 2024. @AzadOncology @Movember @ANZUPtrials @Novartis (@DrMHofman)

@DrRanaMcKay @UCSanDiego and @CaPsurvivorship @DanaFarber discuss the #RadiCaL trial, a phase II study exploring the use of radium in #mRCC with bone metastases and the benefit of Radium-223 with Cabozantinib vs cabozantinib alone. #WatchNow > https://t.co/QlEGZlDf4r @theNCI (@urotoday)

Lutathera is a wonderful intervention in patients with un-resectable neuroendocrine GI tumours, but it can cause #HF in 2% of the cases @ShefUni_IICD @SheffieldHosp @sheffielduni @BSHeartFailure #CardioTwitter @NICEComms (@AAlMohammad87)

"Safety and disease-related outcomes of #mCRPC patients treated with radium-223 then 177Lu-PSMA in the #RALU study. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss these results on UroToday > https://t.co/XJS9XTt2jh @Bayer" (@urotoday)

#AACR23 poster w/ Drs. @SusanneArnoldMD @AmanChauhanMD for #ETCTN (10388): First in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). https://t.co/79XJntQkIM (@NCICTEP_ClinRes)

The @AACR Annual Meeting is underway with some of our experts presenting the latest data on #NETs❗️18 Apr, Tue, @AmanChauhanMD | ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive GEP-NETs (@net_connectinfo)

"Safety and disease-related outcomes of #mCRPC patients treated with radium-223 then 177Lu-PSMA in the #RALU study. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss these results on UroToday > https://t.co/XJS9XTt2jh @Bayer" (@urotoday)

"Imaging and PET analysis as a prognostic tool for Lu-PSMA-617 treatment in patients with #mCRPC. Phillip Kuo, MD, PhD @uarizona joins @CaPsurvivorship @DanaFarber to discuss findings in a #VISION sub-study. #WatchNow on UroToday > https://t.co/V1vu9vDHAG @Invicro @adacap_news" (@urotoday)

"Imaging and PET analysis as a prognostic tool for Lu-PSMA-617 treatment in patients with #mCRPC. Phillip Kuo, MD, PhD @uarizona joins @CaPsurvivorship @DanaFarber to discuss findings in a #VISION sub-study. #WatchNow on UroToday > https://t.co/V1vu9vDHAG @Invicro @adacap_news" (@urotoday)

#parp (#niraparib) & #Radium223 in #mCRPC #ProstateCancer Safety data rPFS 7.1 months 9/28 pts with PSA declines >50% PSA declines in 3/28 patients Many correlatives. How should this study inform PARP + #LuPSMA studies? https://t.co/wIGOvBRLDq (@Dr_RaviMadan)

Nice summary of combo trials with PSMA-directed RLTs in metastatic #prostatecancer We’re excited to open our @PCFnews supported study @UCSFCancer with @thomashopemd using Abemaciclib to upregulate PSMA expression prior to Pluvicto in #mcrpc @PCF_Science @UCSFimaging (@koshkin85)